CORE
🇺🇦
make metadata, not war
Services
Research
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
4 research outputs found
Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir
Author
Andersson
Andreone
+26 more
Back
Badri
Boulenc
Burger
Chayama
Clissold
Dixit
Feld
Fellenius
Ferenci
Foisy
Hézode
Kumar
Lauffenburger
Lawitz
Lind
Lindberg
Menon
Ogilvie
Poordad
Prichard
Prilosec (omeprazole)
Sekar
Serfaty
Yeh
Zeuzem
Publication venue
'Wiley'
Publication date
Field of study
No full text
Crossref
Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies
Author
Aciphex® (rabeprazole sodium)
Bergstrand
+43 more
Carlsson
Castell
Castro Fernandez
Chey
Dekkers
Delhotal-Landes
Dent
DeVault
Donnellan
Fass
Fitzgerald
Freston
Hatlebakk
Holtmann
Hungin
Hunt
Kahrilas
Katsuki
Kaynard
Labenz
Lee
Ligumsky
Locke
Miner
Nexium® (esomeprazole magnesium)
Nocon
Nojkov
Persson
Peura
Prevacid® (lansoprazole)
Prilosec® (Omeprazole)
Protonix® (pantoprazole sodium)
Richter
Richter
Robinson
Robinson
Robinson
Scholten
Sostek
The Gallup Organization
Vakil
Vakil
Zhang
Publication venue
'Wiley'
Publication date
Field of study
No full text
Crossref
Special Population Studies In Clinical Development: Pharmacokinetic Considerations
Author
A Rane
ADM Kashuba
+126 more
AJ McLean
AJJ Wood
American Academy of Pediatrics Committee on Drugs
American Academy of Pediatrics Committee on Drugs
American Academy of Pediatrics Committee on Drugs
Anonymous
AR Scialli
BF Tregaskis
C Bergquist
CC Lee
Cefzil
Cipro
CP Milne
CS Lee
CW Howden
CX Xie
DA Spyker
DB Webb
DJ Back
DJ Belle
DJ Morgan
DW Cockcroft
E Autret
E Keller
E Singlas
E Tanaka
European Commission Enterprise Directorate-General
European Commission Enterprise Directorate-General
Exelon
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration
Food and Drug Administration and the National Institutes of Health Conference
Food and Drug Administration. Qualifying for pediatric exclusivity under section 505A of the Federal Food
G Levy
G Maletta
GJ Schwartz
GJ Schwartz
GL Kearns
GL Kearns
GL Kearns
H Shirkey
HG Xie
HP Freeman
I Beierle
International Committee on Harmonization
International Conference on Harmonization
International Conference on Harmonization
J Boelaert
J Brockmoller
J George
J Marshall
JA Goldstein
JA Johnston
JF Westphal
JG Gambertoglio
JK Bush
JM Kovarik
JM Kovarik
JM Kovarik
JM Kovarik
JMA Geerven Van
JS Kim
JS Leeder
JT Wilson
JT Wilson
KE Zenk
L Collart
L Murray
LE Gustayson
LJ Lesko
Luvox
LZ Benet
M Rowland
MC Nahata
MD Reed
MD Reed
ME Kitler
MJ Reed
ML Chen
ML Chen
MT Kinirons
MW Foster
P Crome
PID Lee
PL Morselli
Prilosec
R Roberts
RB Merkatz
RE Kauffman
RJ Ptachcinski
RL Breitzka
RNH Pugh
RZ Harris
S Dunn
S Hartter
S Ibrahim
Simulect (basiliximab)
SJ Pamis
SN Cohen
SS Anand
T Andersson
T Bergan
T Furuta
T McRorie
TA Sheldon
V Ozdemir
V Rodighiero
V Sekar
Versed
WC Shyu
WD Figg
Y Caraco
YWF Lam
Publication venue
'Springer Science and Business Media LLC'
Publication date
01/01/2004
Field of study
No full text
Crossref
No full text
No full textNo full text